公开(公告)号：EP2366684A1

公开(公告)日：2011-09-21

申请号：EP09825667.0

申请日：2009-11-05

申请人： Universidade Federal Do Rio De Janeiro

发明人： DA SILVA, Alcides José Monteiro ,  RUMJANEK, Vivian Mary Barral Dold ,  BERGMANN, Bartira Rossi ,  DOS SANTOS, Eduardo Salustiano Jesus ,  COSTA, Paulo Roberto, Ribeiro ,  NETTO, Chaquip Daher ,  LIMA, Wallace, Pacienza ,  DOS SANTOS, Eduardo Caio Torres ,  CAVALCANTE, Moisés Clemente, Marinho ,  SEABRA, Sérgio, Henrique ,  RICA, Sérgio Henrique

IPC分类号： C07C50/22 ,  C07C50/00 ,  A61P35/00 ,  A61P33/00 ,  A61K31/122 ,  A61K31/00 ,  C07C46/00

CPC分类号： C07D493/04 ,  C07B2200/07

摘要： This invention belongs to the chemical-pharmaceutical field. New compounds of pterocarpanquinone family presented in formula (I) according to this invention are capable to be activated by reduction generating alkylating species intracellularly. It presents selective cytotoxic effects particularly on mammalian human and nonhuman cells that divide constantly and are useful in treating diseases and dysfunctions related to the phenomenon of undesired cell proliferation. Such compounds are also effective for the treatment of diseases or dysfunctions related to high levels of TNF-α in human and nonhuman mammals.

摘要翻译： 本发明属于化学制药领域。 在式（I）gemäß呈现给本发明pterocarpanquinone家族的新化合物能够通过还原烷基化生成细胞内物质被激活。 它提出对哺乳动物特别是人类和非人类细胞的选择性细胞毒性效应并不断分裂，可用于治疗与不期望的细胞增殖的现象的疾病和功能障碍有用。 搜索化合物因此为与在人和非人哺乳动物高水平TNF±的疾病或功能障碍治疗有效。